| P50 | author | Attila Tóth | Q42847679 |
| P2093 | author name string | Zoltán Papp | |
| | István Édes | |
| | Andrea Daragó | |
| | Emese Bányai | |
| | Miklós Fagyas | |
| | Ivetta M Siket | |
| | Judit Boczán | |
| | Katalin Úri | |
| P2860 | cites work | Human recombinant ACE2 reduces the progression of diabetic nephropathy | Q41786103 |
| | Endogenous inhibitor of angiotensin converting enzyme in the rat heart | Q44136255 |
| | Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. | Q44200597 |
| | Angiotensin-I-converting enzyme inhibitory peptides from tryptic hydrolysate of bovine alphaS2-casein | Q44205621 |
| | ACE Inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008. | Q44239004 |
| | Inhibition of angiotensin converting enzyme by N-terminal fragments of substance P. | Q44594728 |
| | Hereditary elevation of angiotensin converting enzyme suggesting neurosarcoidosis | Q44705221 |
| | The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League | Q46542420 |
| | Observation of high and low molecular weight inhibitors of angiotensin-converting enzyme in rat lung | Q47331823 |
| | An angiotensin-converting enzyme (ACE) inhibitor in human serum. Increased sensitivity of the serum ACE assay for detecting active sarcoidosis. | Q52620527 |
| | Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. | Q52855193 |
| | Ramipril lowered cardiovascular risk, but vitamin E did not | Q54152721 |
| | Antioxidant, antibacterial and ACE-inhibitory activity of four monofloral honeys in relation to their chemical composition. | Q54303553 |
| | ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and | Q56680457 |
| | A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase | Q22254730 |
| | Increased shedding of angiotensin-converting enzyme by a mutation identified in the stalk region | Q24290510 |
| | A strategy to reduce cardiovascular disease by more than 80% | Q24679592 |
| | Angiotensin I-converting enzyme mutation (Trp1197Stop) causes a dramatic increase in blood ACE | Q28116521 |
| | A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure | Q28328342 |
| | New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure | Q28541744 |
| | Peptides with angiotensin I-converting enzyme (ACE) inhibitory activity from defibrinated, hydrolyzed bovine plasma | Q30870203 |
| | The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not. | Q33899337 |
| | Guidelines on myocardial revascularization | Q34134730 |
| | An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels | Q34262228 |
| | Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). | Q34539439 |
| | Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators | Q34539986 |
| | Preventing microalbuminuria in type 2 diabetes | Q34552302 |
| | A novel splice-site mutation in angiotensin I-converting enzyme (ACE) gene, c.3691+1G>A (IVS25+1G>A), causes a dramatic increase in circulating ACE through deletion of the transmembrane anchor | Q34656201 |
| | Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases | Q34799585 |
| | Analysis of serum angiotensin-converting enzyme | Q34847359 |
| | New perspectives in the renin-angiotensin-aldosterone system (RAAS) I: endogenous angiotensin converting enzyme (ACE) inhibition | Q35137560 |
| | New perspectives in the renin-angiotensin-aldosterone system (RAAS) II: albumin suppresses angiotensin converting enzyme (ACE) activity in human | Q35137588 |
| | Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels | Q35196218 |
| | Recommendations for the management of special populations: racial and ethnic populations | Q35587697 |
| | ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition? | Q36719942 |
| | Plant food-derived Angiotensin I converting enzyme inhibitory peptides | Q37486578 |
| | Mammalian inhibitors of angiotensin converting enzyme (kininase II) | Q40278426 |
| | Inhibition of human peptidyl dipeptidase (angiotensin I converting enzyme: kininase II) by human serum albumin and its fragments | Q40298049 |
| | PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1) | Q40421372 |
| | Recent advances in knowledge of the structure and function of the angiotensin I converting enzyme. | Q40964402 |
| | ??? | Q22242895 |
| | ??? | Q28267062 |
| | Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) | Q57245141 |
| | Measurement of human converting enzyme level by direct radioimmunoassay | Q67246966 |
| | A sensitive two-site sandwich enzyme immunoassay for human angiotensin converting enzyme utilizing monoclonal antibodies | Q67672847 |
| | Inhibition of angiotensin-converting enzyme by des-Leu10-angiotensin I: a potential mechanism of endogenous angiotensin-converting enzyme regulation | Q70136964 |
| | Automated kinetic assay of angiotensin-converting enzyme in serum | Q70137199 |
| | Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Mio | Q70890475 |
| | C-type natriuretic peptide. An endogenous inhibitor of vascular angiotensin-converting enzyme activity | Q71129321 |
| | Development of enzyme-linked immunoassays for human angiotensin I converting enzyme suitable for large-scale studies | Q71503825 |
| | ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collabor | Q72028603 |
| | Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy | Q72220327 |
| | A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease | Q72541490 |
| | Isolation of angiotensin converting enzyme (ACE) binding protein from human serum with an ACE affinity column | Q73118013 |
| | ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites | Q73435170 |
| | Isolation of acein-2, a novel angiotensin-I-converting enzyme inhibitory peptide derived from a tryptic hydrolysate of human plasma | Q73450448 |
| | The angiotensin-converting enzyme gene polymorphism and responses to angiotensins and bradykinin in the human forearm | Q73531791 |
| | Properties and human origin of two angiotensin-I-converting enzyme inhibitory peptides isolated from a tryptic hydrolysate of human serum albumin | Q74086846 |
| | Point mutation in the stalk of angiotensin-converting enzyme causes a dramatic increase in serum angiotensin-converting enzyme but no cardiovascular disease | Q74499654 |
| | Human serum albumin induced hypotension in the postoperative phase of cardiac surgery | Q77434809 |
| | Acein-1, a novel angiotensin-I-converting enzyme inhibitory peptide isolated from tryptic hydrolysate of human plasma | Q77596534 |
| | Hereditary hyper-ACE-emia due to the Pro1199Leu mutation of somatic ACE as a potential pitfall in diagnosis: a first family outside Europe | Q80226539 |
| | Joint societies CVD Prevention Guidelines launched in May 2012 | Q84510247 |
| | ACE inhibitory peptides and antioxidant peptides derived from in vitro digestion hydrolysate of hen egg white lysozyme | Q84940346 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cardiovascular disease | Q389735 |
| P304 | page(s) | e93719 | |
| P577 | publication date | 2014-04-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | New perspectives in the renin-angiotensin-aldosterone system (RAAS) III: endogenous inhibition of angiotensin converting enzyme (ACE) provides protection against cardiovascular diseases | |
| P478 | volume | 9 | |